Rockland Immunochemicals & Cellaria Sign Worldwide Distribution Agreement

Cellaria, LLC recently announced a new distribution partnership with Rockland Immunochemicals, Inc. (Rockland) that gives Rockland the rights to market and sell Cellaria’s high-quality next generation in-vitro disease models and cell culture media worldwide.

With Rockland, Cellaria adds to its growing list of strategic distribution partners, expanding its global market presence and reach. Cellaria’s novel cell culture media and cancer cell models add to Rockland’s arsenal of products targeting cancer research and drug screening.

Cellaria’s cell models express different biomarkers that are directly correlated to the patient specimens used to create the models. The diversity of biomarker expression within similar categories of patients enables researchers to generate drug response and disease progression data that is highly relevant to those individual patients.

“We allow drug and cancer researchers to make much more informed decisions about which populations of patients are more likely to respond effectively to drugs that are under investigation,” said David Deems, CEO of Cellaria. “Rockland’s scientific knowledge and their ability to sell cutting-edge and custom products make them a great fit to represent the innovation that we bring to market.”

James Fendrick, CEO of Rockland stated, ”Cellaria’s offerings will nicely complement Rockland’s existing line of cell culture products including human melanoma cell lines, fetal bovine serum, lysates and collagens.  We are honored that Cellaria chose Rockland to serve as their distribution partner.”

Rockland Immunochemicals, Inc. provides the highest quality antibodies and antibody-based life science tools and services to the academic, biopharma, and diagnostic industries for use in basic research, assay development, preclinical and clinical studies, and bioprocessing. With facilities in Pennsylvania for over 55 years, Rockland manufactures products ideally suited for integration into critical assays such as western blotting, immunohistochemistry (IHC), immunofluorescence microscopy (IF), ELISA, flow cytometry, and 2D imaging. Additional information about Rockland’s life science tools and services can be found on Rockland’s website at

Cellaria creates high-quality next generation in-vitro disease models that reflect the unique nature of a patient’s biology. All of our models begin with tissue from a patient, capturing clinically relevant details that inform model characterization. For cancer, Cellaria’s cell models exhibit molecular and phenotypic characteristics that are highly concordant to the patient. For RNA-mediated iPS cell line derivation, Cellaria’s cell models enable interrogation of disease-specific mechanisms of action. Cellaria’s innovative products and services help lead the research community to more personalized therapeutics – revolutionizing and accelerating the search for a cure.  For more information, visit